BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Samuraciclib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Samuraciclib\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07645651-9099@assetmemo.bio
DTSTAMP:20261121T004514Z
DTSTART;VALUE=DATE:20270714
DTEND;VALUE=DATE:20270715
SUMMARY:Samuraciclib: Phase 1 readout est. (NCT07645651)
DESCRIPTION:Samuraciclib\, phase 1.\nStudy: Samuraciclib for the Treatment 
 of Patients With Resectable\, Borderline Resectable\, or Locally Advanced 
 Basal Pancreatic Cancer\nEstimated primary completion: 14 July 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/samuraciclib#upcoming-even
 ts\nRegistry record: https://clinicaltrials.gov/study/NCT07645651
URL:https://assetmemo.bio/drug/samuraciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07665684-9099@assetmemo.bio
DTSTAMP:20261121T004514Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:Samuraciclib: Phase 1/2 readout est. (NCT07665684)
DESCRIPTION:Samuraciclib\, phase 1/2.\nStudy: Samuraciclib in Combination W
 ith Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Panc
 reatic Cancer\nEstimated primary completion: May 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/samuraciclib#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07665684
URL:https://assetmemo.bio/drug/samuraciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04802759-9099@assetmemo.bio
DTSTAMP:20261121T004514Z
DTSTART;VALUE=DATE:20290530
DTEND;VALUE=DATE:20290531
SUMMARY:Samuraciclib: Phase 1/2 readout est. (NCT04802759)
DESCRIPTION:Samuraciclib\, phase 1/2\, HR+/HER2- Metastatic Breast Cancer.\
 nStudy: A Study Evaluating the Efficacy and Safety of Multiple Treatment C
 ombinations in Participants With Breast Cancer\nEstimated primary completi
 on: 30 May 2029. This is a ClinicalTrials.gov estimate\, not a confirmed r
 eadout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/samu
 raciclib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT04802759
URL:https://assetmemo.bio/drug/samuraciclib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
